Clover Health (CLOV) Stock Jumps 14% on Medicare Star Rating Boost to 4.5

Key Highlights

Table of Contents

Clover Health (CLOV) shares jumped approximately 14%, finishing at $4.89, following CMS’s decision to raise its Medicare star rating from 3.5 to 4.5 Stars.
A federal court decision compelled CMS to reassess the rating for Clover’s PPO Medicare Advantage plan under Contract H5141.
This upgraded rating has immediate implications for 2027 reimbursement rates and grants access to quality bonus payments from CMS.
CLOV reached a fresh 52-week peak of $5.14 during trading and marked its third consecutive session of gains.
The rally occurred against a backdrop of broader market declines, with major indices including the S&P 500, Dow Jones, and Nasdaq all posting losses.

Clover Health (CLOV) shares finished Wednesday’s trading session up 13.99% at $4.89, reaching an intraday peak of $5.14, following the company’s announcement of a significant Medicare star rating enhancement from the Centers for Medicare & Medicaid Services.

Clover Health Investments, Corp., CLOV

The healthcare stock has now posted gains for three consecutive sessions and achieved a new 52-week high during Wednesday’s trading.

The driving force: CMS revised CLOV’s 2026 Medicare star rating upward to 4.5 Stars from 3.5 Stars after a court decision in the company’s favor.

This rating revision affects Contract H5141, representing Clover’s PPO Medicare Advantage offering, which encompasses over 97% of the company’s membership base.

The adjusted rating will have direct ramifications for 2027 payment schedules, including qualification for quality-based bonus payments from CMS — representing tangible financial benefits beyond mere reputational gains.

Court Ruling Drives Rating Revision

The rating adjustment resulted from a contentious legal battle. Clover filed suit against CMS and the U.S. Department of Health and Human Services, contending that the agency had employed “improper” quality measurement standards and calculation methods when determining its initial 3.5-star rating.

Clover maintained that the accurate rating should have been 4.0 Stars, asserting that the reduced rating would result in substantial losses in quality bonuses and government payments, diminish its market position, and hamper expansion efforts.

On May 29, 2026, the U.S. District Court for the Southern District of Georgia ruled in Clover’s favor, vacating the original rating and mandating CMS to recalculate.

CMS informed Clover of the revised 4.5-star rating on June 9 — exceeding even Clover’s initial claim.

Strong Earnings Providing Additional Support

The star rating announcement builds on an already strengthening operational foundation.

Clover delivered its inaugural positive GAAP net income during Q1 2026, accompanied by substantial year-over-year revenue growth.

Canaccord analyst Richard Close recently increased his price target on the stock while maintaining a Buy recommendation. He noted that improving trends in managed care were creating tailwinds for digital health enterprises.

This positive fundamental context encouraged investors to respond decisively to Wednesday’s announcement.

The stock’s performance was particularly remarkable considering the challenging market conditions on the day.

The May 2026 CPI data, published Wednesday morning, revealed headline inflation accelerating to 4.2% on a year-over-year basis — marking the highest reading since 2023 — fueled by surging energy prices linked to geopolitical instability.

The S&P 500, Dow Jones, and Nasdaq all declined during the session in response.

CLOV defied this broader weakness convincingly, propelled by a company-specific legal victory carrying measurable financial implications.

CMS formally notified Clover of the enhanced 4.5-star rating on June 9, 2026.